Original Investigation

Psychopharmacology

, Volume 193, Issue 1, pp 121-136

First online:

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

  • Linda M. Rorick-KehnAffiliated withNeuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company Email author 
  • , Bryan G. JohnsonAffiliated withNeuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company
  • , Karen M. KnitowskiAffiliated withNeuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company
  • , Craig R. SalhoffAffiliated withNeuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company
  • , Jeffrey M. WitkinAffiliated withNeuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company
  • , Kenneth W. PerryAffiliated withNeuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company
  • , Kelly I. GriffeyAffiliated withNeuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company
  • , Joseph P. TizzanoAffiliated withDOV Pharmaceuticals, Continental Plaza
  • , James A. MonnAffiliated withNeuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company
    • , David L. McKinzieAffiliated withNeuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company
    • , Darryle D. SchoeppAffiliated withNeuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Rationale

Data from both preclinical and clinical studies have provided proof of concept that modulation of limbic and forebrain glutamate, via mGlu2/3 receptor agonists, might provide therapeutic benefits in many psychiatric disorders including schizophrenia and anxiety.

Objective

The aim of this study was to assess the efficacy of a structurally novel, potent, selective mGlu2/3 receptor agonist with improved bioavailability (LY404039) in animal models predictive of antipsychotic and anxiolytic efficacy.

Materials and methods

LY404039 was assessed in amphetamine- and phencyclidine-induced hyperlocomotion, conditioned avoidance responding, fear-potentiated startle, marble burying, and rotarod behavioral tests. Monoamine release and turnover were assessed using microdialysis and ex vivo tissue levels.

Results

LY404039 attenuated amphetamine- and phencyclidine-induced hyperlocomotion (3–30 and 10 mg/kg, respectively). LY404039 (3–10 mg/kg) inhibited conditioned avoidance responding. LY404039 also reduced fear-potentiated startle in rats (3–30 μg/kg) and marble burying in mice (3–10 mg/kg), indicating anxiolytic-like effects. Importantly, LY404039 did not produce sedative effects or motor impairment as measured by rotarod performance and lack of escape failures in the conditioned avoidance task (at doses up to 30 and 10 mg/kg, respectively). LY404039 (10 mg/kg) also increased dopamine and serotonin release/turnover in the prefrontal cortex.

Conclusions

These results demonstrate the broad preclinical efficacy of LY404039 across multiple animal models of antipsychotic and anxiolytic efficacy. Additionally, this compound modulates mesocortical neurotransmission and provides a novel mechanism for the treatment of psychiatric disorders that may be associated with improved efficacy and reduced incidence of undesirable side effects. As glutamatergic dysfunction has been linked to the etiology of schizophrenia, clinical studies with more potent mGlu2/3 agonists, such as LY404039, may be useful to explore the validity of this hypothesis.

Keywords

Metabotropic glutamate (mGlu) receptors mGlu2/3 receptor agonist Anxiety Schizophrenia Psychiatric disorders Animal models Anxiolytic Antipsychotic